Celator Pharma Announces Publication Of Phase 2 Study On CPX-351 - Quick Facts

(RTTNews) - Celator Pharmaceuticals, Inc. (CPXX) announced the publication of the Phase 2 study evaluating CPX-351 in newly diagnosed older patients with acute myeloid leukemia. The company said the data, along with results from the Phase 2 study of CPX-351 in patients with acute myeloid leukemia in first relapse, support Celator's currently-enrolling Phase 3 study of CPX-351 as a first-line therapy in older patients with high-risk acute myeloid leukemia.

The randomized, controlled, Phase 2 study evaluated 126 patients, aged 60-75 years, from 18 clinical centers in the U.S. and Canada, with newly diagnosed, pathologically confirmed acute myeloid leukemia. Results showed that CPX-351 treatment was associated with higher complete response rate, prolonged event-free survival and overall survival. Treatment with CPX-351 was associated with well-characterized and manageable adverse events, the company said.

Arthur Louie, Chief Medical Officer of Celator, said: "These data suggest an enhanced clinical benefit of CPX-351 over the current standard of care, known as the 7+3 regimen, and we hope to further validate these findings with our Phase 3 study, with initial data expected in the second quarter of 2015."